The real revolution came in 2012, when researchers Jennifer Doudna and Emmanuelle Charpentier harnessed CRISPR, a natural bacterial defense system. In bacteria, CRISPR cuts out invading viruses’ DNA ...
By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...
Zacks Small Cap Research on MSN
DYAI: Purchase Orders Rolling In
DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic Applied BioSolutions, Inc. (NASDAQ:DYAI) announced third quarter 2025 results on November 12th, 2025, and held a conference call to discuss them after ...
According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...
Ecuadorian scientists have, for the first time, edited the gene of a fungus that destroys banana plantations. Using an ...
Scientists at St. Jude Children's Research Hospital and Northwestern University identified a previously unknown treatment ...
In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and ...
ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global biotechnology ...
CRISPR-Cas9 is a promising approach for obesity therapy, targeting key genes involved in appetite regulation, metabolism, and ...
ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered ...
Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback